Research map: Paclitaxel and carboplatin after disease progression on immune checkpoint inhibitor for patients with metastatic urothelial carcinoma

Back to the article

Papers in this map

  1. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) · E. A. Eisenhauer · 2008 · 30146 citations · Cited by this paper
  2. Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer · 2026 · Related
  3. Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma · Dean F. Bajorin · 2021 · 1090 citations · Cited by this paper
  4. FDA 2025 Cancer Drug Approvals: targeted therapy dominates · 2026 · Related
  5. Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer · Thomas B. Powles · 2024 · 1079 citations · Cited by this paper
  6. Racial disparities in hepatocellular carcinoma: a TCGA-based gene expression study of Caucasian and Asian populations · 2025 · Related
  7. Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial · Funda Meric‐Bernstam · 2023 · 1061 citations · Cited by this paper
  8. Metabolic plasticity drives specific mechanisms of chemotherapy and targeted therapy resistance in metastatic colorectal cancer · 2025 · Related
  9. Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer · Thomas B. Powles · 2024 · 403 citations · Cited by this paper
  10. Benign, persistent, and invasive: mechanistic and translational approaches to middle‑ear cholesteatoma · 2026 · Related
  11. Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer · John K. Chan · 2016 · 369 citations · Cited by this paper
  12. Lorlatinib in advanced ALK-positive NSCLC after prior progression on ALK inhibitors: real-world experience in Russia · 2026 · Related
  13. Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma · Yohann Loriot · 2023 · 337 citations · Cited by this paper
  14. Reactive oxygen species (ROS) in cancer: from redox signaling and metabolic plasticity to therapeutic vulnerabilities · 2026 · Related
  15. Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer · Christof Vulsteke · 2026 · 103 citations · Cited by this paper
  16. Liquid biopsy in breast cancer: current biomarker platforms and clinical applications · 2026 · Related
  17. Excellent response to chemotherapy post immunotherapy · Ashish Dutta Dwary · 2017 · 67 citations · Cited by this paper
  18. More than alternative estrogen receptors: the emerging role of GPER-1 and ERα36 in breast cancer · 2026 · Related
  19. Phase II trial of carboplatin and paclitaxel in cisplatin‐pretreated advanced transitional cell carcinoma · Ulka N. Vaishampayan · 2005 · 55 citations · Cited by this paper
  20. Paclitaxel and carboplatin in bladder cancer · David J. Vaughn · 2000 · 28 citations · Cited by this paper
  21. Immunotherapies in Genitourinary Oncology: Where Are We Now? Where Are We Going? · Albert Jang · 2021 · 24 citations · Cited by this paper
  22. Weekly Carboplatin and Paclitaxel: A Retrospective Comparison with the Three-Weekly Schedule in First-Line Treatment of Ovarian Cancer · Tamar Safra · 2020 · 22 citations · Cited by this paper
  23. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer · Matt D. Galsky · 2026 · 13 citations · Cited by this paper
  24. Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis · Cláudia Marchetti · 2016 · 12 citations · Cited by this paper
  25. Tolerance of weekly metronomic paclitaxel and carboplatin as neoadjuvant chemotherapy in advanced ovarian cancer patients who are unlikely to tolerate 3 weekly paclitaxel and carboplatin · S B Dessai · 2016 · 11 citations · Cited by this paper
  26. Paclitaxel and carboplatin chemotherapy after platinum‑based chemotherapy and pembrolizumab for metastatic urothelial carcinoma · Nobuki Furubayashi · 2021 · 7 citations · Cited by this paper
  27. Chemoimmunotherapy after progression on single-agent pembrolizumab for metastatic urothelial carcinoma: a case series · Daniel S. Childs · 2021 · 2 citations · Cited by this paper
  28. Untitled · Cited by this paper
  29. Untitled · Cited by this paper
  30. Untitled · Cited by this paper
  31. Untitled · Cited by this paper
  32. Untitled · Cited by this paper

Source: OpenAlex (CC0)